BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20829006)

  • 1. Correlation of currently used radiobiological parameters with local control and acute and late mucosal toxicity in randomised studies of altered fractionation for locally advanced head and neck cancer.
    Hartley A; Sanghera P; Kazi W; Mehanna H; McConkey C; Glaholm J; Fowler J
    Clin Oncol (R Coll Radiol); 2011 Feb; 23(1):29-33. PubMed ID: 20829006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated accelerated radiotherapy with concurrent carboplatin for locally advanced squamous cell carcinoma of the head and neck.
    Chan AK; Sanghera P; Choo BA; McConkey C; Mehanna H; Parmar S; Pracy P; Glaholm J; Hartley A
    Clin Oncol (R Coll Radiol); 2011 Feb; 23(1):34-9. PubMed ID: 20863676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiobiological modelling of the therapeutic ratio for the addition of synchronous chemotherapy to radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
    Hartley A; Sanghera P; Glaholm J; Mehanna H; McConkey C; Fowler J
    Clin Oncol (R Coll Radiol); 2010 Mar; 22(2):125-30. PubMed ID: 19880297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
    Corvò R
    Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy and chemotherapy in locally advanced head and neck squamous cell carcinoma.
    Krstevska V
    J BUON; 2009; 14(3):361-73. PubMed ID: 19810125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of low-dose daily cisplatin on the distant metastasis-free survival of patients with locally advanced nonmetastatic head and neck cancer treated with radiation therapy.
    Jeremić B; Milicić B
    Radiother Oncol; 2008 May; 87(2):201-3. PubMed ID: 18207598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules.
    Moreno-Jiménez M; Valero J; López-Picazo JM; Arbea L; Aristu J; Cambeiro M; Alcalde J; Martínez-Monge R
    Am J Clin Oncol; 2010 Apr; 33(2):137-43. PubMed ID: 19786847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.
    Huguenin P; Beer KT; Allal A; Rufibach K; Friedli C; Davis JB; Pestalozzi B; Schmid S; Thöni A; Ozsahin M; Bernier J; Töpfer M; Kann R; Meier UR; Thum P; Bieri S; Notter M; Lombriser N; Glanzmann C
    J Clin Oncol; 2004 Dec; 22(23):4665-73. PubMed ID: 15534360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
    Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
    Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study.
    Hehr T; Classen J; Welz S; Ganswindt U; Scheithauer H; Koitschev A; Bamberg M; Budach W
    Radiother Oncol; 2006 Jul; 80(1):33-8. PubMed ID: 16875750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma.
    Rosenthal DI; Ang KK
    Semin Radiat Oncol; 2004 Apr; 14(2):153-66. PubMed ID: 15095261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant administration of two standard regimens of chemotherapy and radiotherapy in advanced squamous carcinoma of the head and neck: a feasibility study.
    Benasso M; Corvò R; Numico G; Cavallari M; Blengio F; Sanguineti G; Rosso M; Merlano M
    Anticancer Res; 1995; 15(6B):2651-4. PubMed ID: 8669841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
    Budach W; Hehr T; Budach V; Belka C; Dietz K
    BMC Cancer; 2006 Jan; 6():28. PubMed ID: 16448551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer.
    Guerrero Urbano T; Clark CH; Hansen VN; Adams EJ; A'Hern R; Miles EA; McNair H; Bidmead M; Warrington AP; Dearnaley DP; Harrington KJ; Nutting CM
    Radiother Oncol; 2007 Oct; 85(1):36-41. PubMed ID: 17709149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer.
    Newlin HE; Amdur RJ; Riggs CE; Morris CG; Kirwan JM; Mendenhall WM
    Cancer; 2010 Oct; 116(19):4533-40. PubMed ID: 20572028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure.
    Frank SJ; Rosenthal DI; Petsuksiri J; Ang KK; Morrison WH; Weber RS; Glisson BS; Chao KS; Schwartz DL; Chronowski GM; El-Naggar AK; Garden AS
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1005-10. PubMed ID: 20207504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
    Klem ML; Mechalakos JG; Wolden SL; Zelefsky MJ; Singh B; Kraus D; Shaha A; Shah J; Pfister DG; Lee NY
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1100-7. PubMed ID: 17980501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.